Showing results (281-290 of 298) with videos related to

Sort By:
Pageof 30
Archives of General Psychiatry|July 1, 1996
Auditory attentional deficits in patients with schizophrenia. A positron emission tomography studyD S O'Leary, N C Andreasen, R R Hurtig, et al.
Nature|August 31, 2012
Potential methane reservoirs beneath AntarcticaJ L Wadham, S Arndt, S Tulaczyk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Intrathecal mafosfamide: a preclinical pharmacology and phase I trialSusan M Blaney, Frank M Balis, Stacey Berg, et al.
HNO|October 19, 2012
[Evaluation of the Freiburg monosyllabic speech test in background noise]J Löhler, B Akcicek, M Pilnik, et al.
International Journal of Radiation Oncology, Biology, Physics|October 15, 2022
Proton Whole-Lung Irradiation: Initial Report of OutcomesDanielle A Cunningham, William G Breen, Jedediah E Johnson, et al.
Behavioural Brain Research|April 1, 2014
No role for vitamin D or a moderate fat diet in aging induced cognitive decline and emotional reactivity in C57BL/6 miceE M Brouwer-Brolsma, T Schuurman, L C P M G de Groot, et al.
Neuroreport|April 11, 2000
Cerebellar hypoactivity in frequent marijuana usersR I Block, D S O'Leary, R D Hichwa, et al.
Cancer Medicine|August 29, 2019
Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology GroupEmily Hibbitts, Yueh-Yun Chi, Douglas S Hawkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2009
Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803Carola A S Arndt, Julie A Stoner, Douglas S Hawkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2010
Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology GroupCarola A S Arndt, Nadya V Koshkina, Carrie Y Inwards, et al.
Pageof 30